CUA

Glytec Announces Patrick F. Cua as Chief Executive Officer

Retrieved on: 
Thursday, January 4, 2024
Brain damage, EHR, Agency, Risk, CUA, Acquisition, Software as a service, AHRQ, Glucommander, Hospital, Hyperglycemia, Medicare, Infection, Growth, Patient, Organization, Seizure, Hypoglycemia, CMS

WALTHAM, Mass., Jan. 4, 2024 /PRNewswire/ -- Glytec, the only provider of cloud-based insulin management software as a service (SaaS) solutions across the continuum of care, today announced the appointment of Patrick F. Cua as Chief Executive Officer. In his new role, Cua will prepare the company for rapid growth to meet increasing demand for Glucommander amid a surging industry focus on healthcare outcomes, cost savings, diabetes technology, and glycemic management.

Key Points: 
  • WALTHAM, Mass., Jan. 4, 2024 /PRNewswire/ -- Glytec , the only provider of cloud-based insulin management software as a service (SaaS) solutions across the continuum of care, today announced the appointment of Patrick F. Cua as Chief Executive Officer.
  • "Glytec is an early innovator for inpatient glycemic management SaaS and has built and maintained a reputation as the trusted partner for healthcare providers," said Cua.
  • I'm excited to grow the organization and scale its technology through this transformative time, not just for Glytec, but also for healthcare and the diabetes technology industry."
  • To learn more about Glytec and its insulin management software, visit https://glytecsystems.com/ .

SENIOR ACADEMIC PHILANTHROPY LEADER KIM M. MORTON, JD, MA, NAMED NEW ASSOCIATE DEAN FOR DEVELOPMENT AT UNIVERSITY OF MARYLAND MEDICINE

Retrieved on: 
Tuesday, November 28, 2023
Johns Hopkins University, School, JD, Associate, JHU, Research, The, Senior, Hope, Maryland School, Dean (education), UMMC, Student, Patient, Faculty, Culture, UMM, Trust, War Doctor, Wellesley College, Friends, Wilmer Ophthalmological Institute, University, Development, Bryn Mawr School, Education, George Washington University, Catholic higher education, Volunteering, Health, Hospital, CUA, Bachelor of Arts, Management, Boston, MD, Neurology

BALTIMORE, Nov. 28, 2023 /PRNewswire/ -- University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, along with University of Maryland Medical Center (UMMC) President and CEO, Bert W. O'Malley, MD, announced today that Kim M. Morton, JD, MA, who has led advancement operations for major academic and healthcare institutions during her career, will become Associate Dean for Development at University of Maryland Medicine Philanthropy, the joint advancement operation of the UMSOM and UMMC. Ms. Morton, who was selected as the top candidate, following a national search, will report to Heather Culp, Senior Vice President, Chief Philanthropy Officer and Senior Associate Dean. Her appointment will begin December 18.

Key Points: 
  • Ms. Morton, who was selected as the top candidate, following a national search, will report to Heather Culp, Senior Vice President, Chief Philanthropy Officer and Senior Associate Dean.
  • The appointment of Ms. Morton follows the recent alignment of the UMSOM and UMMC Development Offices under the leadership of Ms. Culp as Chief Philanthropy Officer for the combined entity, University of Maryland Medicine Philanthropy.
  • "It is a particularly exciting and dynamic time right now at the University of Maryland Medicine," said Dean Gladwin.
  • "I am excited to partner with Heather Culp, Dean Gladwin, Dr. O'Malley, and the talented team at University of Maryland Medicine Philanthropy," Ms. Morton said.

DGAP-News: Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational N

Retrieved on: 
Wednesday, June 15, 2022
Multiple sclerosis, Calcium, Cleveland Clinic, NEW, CUA, Safety, Infection, Lists of academic journals, Liver, Research, Neurology, Muscle atrophy, Magnetic resonance imaging, Degenerative disease, Barrow Neurological Institute, RMS, Cohort, Nasdaq, Emphasis, MRI, Patient, DHODH, RRMS, Translation, Pharmaceutical industry, Medical imaging, Short course immune induction therapy

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational N

Key Points: 
  • Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational N
    The issuer is solely responsible for the content of this announcement.
  • The inhibition of DHODH has been shown to suppress magnetic resonance imaging (MRI) brain lesions and disease activity in multiple sclerosis.
  • The paper assessed the safety and activity on MRI-based endpoints as well as clinical and biomarker assessments of vidofludimus calcium in patients with RRMS.
  • Equally exciting, we have also been enrolling patients in our phase 3 ENSURE program of vidofludimus calcium as a treatment for relapsing multiple sclerosis (RMS).

Study: Massachusetts Hospitals Pull Back on Charity Care as Revenue from Federal 340B Drug Discount Program Explodes

Retrieved on: 
Tuesday, March 22, 2022
Catholic higher education, Gordon College, Public policy, Catholic University of America, Harvard Kennedy School, Pharmacy, Economics, Health, Transport, Growth, Biotechnology, The, Doctor of Philosophy, White, Program, Government, Capitol Hill, Apothecary (film), Hospital, Fellow, Pioneer Institute, Pioneer, House, PBM, Harvard University, White House, Pfizer, Goal, Forbes, List of life sciences, Policy, Blog, CUA, Ministry of Women and Vulnerable Populations, Founder, Education, Patient, Health insurance, Management

The Pioneer Institute study, " 340B Drug Discounts: An Increasingly Dysfunctional Program ," notes that nationwide, 340B drug sales rose from $9 billion in 2014 to $38 billion in 2020.

Key Points: 
  • The Pioneer Institute study, " 340B Drug Discounts: An Increasingly Dysfunctional Program ," notes that nationwide, 340B drug sales rose from $9 billion in 2014 to $38 billion in 2020.
  • "The 340B program has, unfortunately, been transformed into a lucrative revenue stream for hospitals and pharmacies who can arbitrage drug discounts.
  • With the exception of a small number of dedicated hospitals and clinics, the original goals of the program have largely been lost."
  • The report argues that the nonprofit tax treatment of hospitals, as well as their participation in the 340B program, should lend itself to more generous provision of charity care for vulnerable populations.

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Retrieved on: 
Monday, November 22, 2021
Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, Population, FDI, University, Disease, Peripheral artery disease, Pain, Pharma, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, Balearic Islands, Wound healing, Vifor Pharma, Chronic kidney disease, Mortality, Dialysis, PAD, Cardiovascular disease, Fine chemical, Pharmaceutical industry

Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.

Key Points: 
  • Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the companys portfolio of innovative assets.
  • Todays exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group.
  • We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies.

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Retrieved on: 
Monday, November 22, 2021
Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, Population, FDI, University, Disease, Peripheral artery disease, Pain, Pharma, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, Balearic Islands, Wound healing, Vifor Pharma, Chronic kidney disease, Mortality, Dialysis, PAD, Cardiovascular disease, Fine chemical, Pharmaceutical industry

Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.

Key Points: 
  • Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the companys portfolio of innovative assets.
  • Todays exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group.
  • We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies.

Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG

Retrieved on: 
Monday, November 22, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Patient, European Medicines Agency, US Foods, Nephrology, Acquisition, LR, Population, ART, FDI, University, Disease, Pain, Generalized arterial calcification of infancy, CUA, CALIPSO, EUR, University of the Balearic Islands, Calcification, CET, Balearic Islands, Wound healing, Foreign direct investment, CHF, Vifor Pharma, Lead, AVS, Chronic kidney disease, Mortality, Calcifying odontogenic cyst, Dialysis, PAD, Cardiovascular disease, CKD, Pharmaceutical industry, Vifor Pharma Group, SNF472, INS-3001, CUA, PAD, AVS, VIFOR PHARMA GROUP, SNF472, INS-3001, CUA, PAD, AVS

53 LR

Key Points: 
  • 53 LR
    Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.
  • Through these acquisitions, Vifor Pharma will be able to serve a continuum of vascular calcification disorders at all stages of CKD.
  • Acquisition of Sanifit is for the continued clinical development and commercialization of SNF472, a novel, first-in-class intravenously administered inhibitor of vascular calcification, for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Vifor Pharma will acquire 100% of the shares in Inositec AG, receiving full global rights for the lead asset INS-3001.

Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat

Retrieved on: 
Tuesday, November 9, 2021
Mortality, House, Public health, White House, Cancer, Catholic higher education, Capitol Hill, Pioneer, Color, Policy, Telehealth, Government, Health, Center, Education, White, Degenerative disease, The, Doctor of Philosophy, Transport, Pfizer, Atorvastatin, JAMA, COVID-19, USPSTF, American Medical Association, List of life sciences, Cardiovascular disease, Vaccine, Biotechnology, Prescription, Therapy, Journal, Diagnosis, Death, Time, Catholic University of America, Patient, Pioneer Institute, Public, CUA, Pharmaceutical industry, Medical device, Management

, that examines how the COVID-19 pandemic has created another unrelated public health crisis.

Key Points: 
  • , that examines how the COVID-19 pandemic has created another unrelated public health crisis.
  • "But during that time, public health officials have ignored the need to make repeated calls to at-risk populations to visit the doctor and get important health screenings.
  • In the absence of these important prevention efforts, we are on the brink of a public health challenge, worsening patient outcomes, and additional healthcare costs."
  • The U.S. Preventive Services Task Force (USPSTF) should submit recommendations on how to mitigate public health damage that may have occurred from the precipitous drop in health screenings.

MK Decision and Credit Union Awareness Partner to Grow Credit Union Membership through Digital Account Opening

Retrieved on: 
Thursday, March 18, 2021
Mixed economies, CUA, Credit union

SAN DIEGO, March 18, 2021 /PRNewswire-PRWeb/ --California-based FinTech, MK Decision (MK) announced its partnership with Credit Union National Association 's subsidiary CU Awareness, LLC (CUA) to increase member conversions by empowering credit unions with MK's digital account opening platform.

Key Points: 
  • SAN DIEGO, March 18, 2021 /PRNewswire-PRWeb/ --California-based FinTech, MK Decision (MK) announced its partnership with Credit Union National Association 's subsidiary CU Awareness, LLC (CUA) to increase member conversions by empowering credit unions with MK's digital account opening platform.
  • CUA's Open Your Eyes to a Credit Union digital campaign continues to exponentially grow its reach and connection with consumers.
  • Amidst the pandemic, MK's platform offers an intuitive, online shopping experience to start the first transaction in the credit union relationship, opening a deposit account.
  • To take back account opening market share, CUA and MK committed to providing credit unions the critical online infrastructure needed to support their members.

Servus Credit Union Announces Ian Burns as New President & CEO

Retrieved on: 
Thursday, March 11, 2021
Credit unions of Canada, Financial services, Finance, Banking, Servus Credit Union, Canadian Credit Union Association, Credit union, CUA, Interac

Servuss Board of Directors is pleased to announce that weve selected Ian Burns as Servuss next President and CEO, said Servus Credit Unions Board Chair John Lamb.

Key Points: 
  • Servuss Board of Directors is pleased to announce that weve selected Ian Burns as Servuss next President and CEO, said Servus Credit Unions Board Chair John Lamb.
  • Mr. Burns has served as CEO for Credit Union Central Alberta since 2018.
  • He serves on a number of boards within the Canadian credit union and financial industry systems including Interac, Celero, Everlink and the Canadian Credit Union Association (CCUA).
  • About Servus Credit Union Ltd.
    At Servus Credit Union we're building a better world, one member at a time.